STAR-CRISPR
LIVE

Serial Number

79426106

Owner

Celyntra Therapeutics SA

Attorney

Jessica S. Sachs

Filing Date

May 13, 2025

Add to watchlist:

No watchlists yet
View on USPTO

STAR-CRISPR Trademark

Serial Number: 79426106 • Registration: 8172915

STAR-CRISPR is a trademark filed by Celyntra Therapeutics SA on May 13, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Celyntra Therapeutics SA (9 trademarks)

Rue Edouard Belin 2

Entity Type: 33

Trademark Details

Filing Date

May 13, 2025

Registration Date

March 17, 2026

Published for Opposition

January 27, 2026

Goods & Services

Reagents for research purposes; reagents used in science; reagents for scientific purposes; reagents for medical research; laboratory reagents for scientific use; chemical reagents for scientific purposes; reagents for scientific or medical research use; chemical reagents for use in genetic research; chemical reagents for use in biotechnology, other than for medical or veterinary use; specialized reagents for genome editing for scientific, research, and laboratory use; modified cells, in particular genetically modified ips (induced pluripotent stem) cells and differentiated cells derived therefrom, for research or scientific purposes; cell cultures, cell culture systems and cryopreserved genetically modified ips cells for scientific and industrial research purposes; cell cultures, and cryopreserved cells ips cells other than for medical or veterinary use; Biological preparations for use in cell cultures, other than for medical or veterinary purposes, namely, cell culture agents for use in the biotechnology industry and cell material for use in combination with human cells, including genetically modified ips or differentiated stem cells

Medical diagnostic reagents; clinical medical reagents; clinical diagnostic reagents for medical use; reagents for use in medical genetic testing; cells for medical use; genetic identity tests comprised of reagents for medical purposes; specialized reagents for genome editing for medical and medical clinical use; modified cells, in particular genetically modified ips (induced pluripotent stem) cells and differentiated cells derived therefrom, for medical or veterinary use; cell cultures and cell culture systems, and cryopreserved pluripotent stem cells for medical or veterinary use; genetically modified ips (induced pluripotent stem) cells for use in generating other cells for therapeutic purposes; cell cultures and cell culture systems, and cryopreserved genetically modified pluripotent stem cells for sub cultivation of cells, for medical or veterinary use

Custom manufacturing of iPS derived cells, and iPS derived cell therapy and manufacturing processes for others, namely, manufacturing of the foregoing cells in GMP-based facilities; custom manufacture of therapeutic cells, medicines, cell therapies and gene edited cell therapies for others, including manufacturing in GMP-based facilities; custom manufacture of cellular therapies, including manufacturing in GMP-based facilities; manufacturing of cell lines being modified cells with specific genetic edits for use in generating other cells

Structural and functional analysis of genomes; research and development in the field of microorganisms and cells; research in the field of gene editing technology; genetic research; gene therapy research; scientific research in the field of genetics and genetic engineering; research in the field of gene therapy; research in the field of genetic diseases; scientific research relating to genetics; biotechnology research; biotechnology testing; preparation of reports in the biotechnology field; research and testing of cell-based products, in particular therapeutic products; research, optimization and testing of cell production processes; laboratory research in the field of biotechnology using genetically modified ips (induced pluripotent stem) cells and differentiated cells derived therefrom; scientific research, design and development of scientific cell culture, cell therapy and gene edited cell therapy; scientific research, design and development of cell culture, cell therapy and gene edited cell therapy, manufacturing systems and manufacturing processes for others; platform as a service (PAAS) services featuring computer software platforms for custom manufacturing of cell-based products in the field of cell therapy, and cell therapy development; providing temporary use of online non-downloadable computer software platform for the management of manufacturing of cell-based therapies, namely, the associated technology, processes, and data analytics capabilities for process optimization and quality control

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 17, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 17, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 17, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 27, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jan 27, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 21, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 6, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 5, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 5, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 5, 2026 TROA
REFUSAL PROCESSED BY IB
Nov 22, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 5, 2025 RFCS
REFUSAL PROCESSED BY MPU
Nov 5, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 17, 2025 RFCR
NON-FINAL ACTION WRITTEN
Sep 16, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 3, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 22, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 22, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 19, 2025 REPR